Daiichi Sankyo

Daiichi Sankyo is a pharmaceutical corporation headquartered in Tokyo, Japan. It was created as a result of a merger between Sankyo Company, Limited, and Daiichi Pharmaceutical Company, Limited. It has approximately 32,000 employees worldwide. In 2013, Daiichi Sankyo was the fourth largest pharmaceutical corporation in Japan and the 20th in the world in terms of net sales. The corporation considers Olmetec (olmertasan), an antihypertensive agent, its main product. Daiichi Sankyo also produces Rezaltas, a combination drug containing olmesartan medoxomil and a long-acting calcium channel blocker, azelnidipine. Two other major products are Prasugrel, which is an antiplatelet agent, and Edoxaban, which is an anticoagulant. The drugs Memary, which treats Alzheimer’s disease, Nexium, which treats reflux esophagitis, and Inavir, which is an anti-influenza treatment, are designated as ...